<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01214746</url>
  </required_header>
  <id_info>
    <org_study_id>EBP-FHC-2010-1</org_study_id>
    <nct_id>NCT01214746</nct_id>
  </id_info>
  <brief_title>The Effects of Atorvastatin on the Nitric Oxide-system in Healthy Young Man</brief_title>
  <acronym>STAR</acronym>
  <official_title>The Effects of Atorvastatin on the Nitric Oxide-system in Healthy Young Man</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regional Hospital Holstebro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regional Hospital Holstebro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been documented that statin reduce mortality and morbidity in patients with
      cardiovascular disease. This effect can partly be related to a reduction in cholesterol
      levels in blood. Nitric oxide (NO) production is reduced in several chronic diseases such as
      nephropathy, diabetes and hypertension. The purpose of this study is to investigate the
      effect of Atorvastatin treatment on the NO-system measuring renal and cardiovascular
      variables in healthy man.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be examined on two examination days. 4 days prior to each examination day
      subjects are treated with either atorvastatin or placebo. During treatment periods subject
      are given a standardized diet.

      On the examination days subject are given L-NMMA(L-NG-monomethyl Arginine citrate), a NO
      inhibitor, 6 mg bolus infusion followed by continuous 4 mg/kg/hr infusion for 1 hour. Renal
      function, central hemodynamic and vasoactive hormones are evaluated prior, during and after
      L-NMMA infusion.

      Renal function is measured by renal clearance of 51Cr-EDTA and urinary sodium, potassium and
      albumin concentration. Urinary excretion of protein from sodium channels such as the NaCl
      cotransporter (NCC), the Na-K-Cl cotransporter (NKCC) and the epithelial sodium channel
      (ENaC)will be measured to evaluate channel activity in the nephron.

      Central blood pressure, pulse wave analysis, and augmentation index are measured using
      SphygmoCorÂ® from Atcor.

      The vasoactive hormones aldosterone, renin, angiotensin II, atrial natriuretic peptide (ANP),
      brain natriuretic (BNP) and endothelin is measured in plasma
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fractional excretion of sodium</measure>
    <time_frame>5 days treatment</time_frame>
    <description>Sodium excretion measured before, during and after L-NMMA infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure (SBP)</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma renin concentration</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentation index (AI)</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma aldosterone concentration</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and urinary albumin concentration</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of aquaporin-2</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma atrial natriuretic peptide concentration</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma brain natriuretic peptide concentration</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of protein from sodium channels such as the NaCl cotransporter (NCC), the Na-K-Cl cotransporter (NKCC) and the epithelial sodium channel (ENaC)</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Nephropathy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet Unikalk 1 time pr day for 5 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Unikalk</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Zarator, 80 mg pr day for 5 days</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>Zarator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, age 18-40 years

          -  Body Mass Index (BMI) 18,5-30 kg/m2

        Exclusion Criteria:

          -  Arterial hypertension (&gt;140 mmHg systolic and/or 90 mmHg diastolic)

          -  Anamnestic or clinical signs of heart, lung, lever, kidney and brain disease

          -  Neoplastic disease

          -  Alcohol abuse,

          -  Drug abuse

          -  Medical treatment except oral anticontraceptive

          -  Smoking

          -  Pregnancy or

          -  Abnormal blood and urine sample

          -  Abnormal ECG

          -  Blood donation within a month before examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank H Christensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicinsk Forskning</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicinsk Forskning, Regionshospitalet Holstebro</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2010</study_first_submitted>
  <study_first_submitted_qc>October 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2010</study_first_posted>
  <last_update_submitted>August 15, 2011</last_update_submitted>
  <last_update_submitted_qc>August 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>MD Frank Holden Christensen</name_title>
    <organization>Department of Medical Research, Regionshospitalet Holstebro</organization>
  </responsible_party>
  <keyword>Statin</keyword>
  <keyword>L-NMMA</keyword>
  <keyword>Healthy subjects</keyword>
  <keyword>Nephrology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

